Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281074 | 0.90 | PGK1 (0.57) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL20266993 | 0.87 | SYK (0.45) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL20280944 | 0.84 | CYP1A2 (0.60) | MAPK1KMT2ATDP1CYP1A2CYP3A4 | |
| SCHEMBL20280938 | 0.84 | GLRA3 (0.49) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL20280950 | 0.82 | CYP1A2 (0.45) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL20280942 | 0.78 | CYP1A2 (0.46) | TDP1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20266987 | 0.76 | APP (0.71) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL26203646 | 0.74 | LATS1 (0.41) | CNR2KMT2ATDP1L3MBTL1CYP1A2 | |
| SCHEMBL20281126 | 0.74 | LATS1 (0.41) | CNR2KMT2ATDP1L3MBTL1CYP1A2 | |
| SCHEMBL8177852 | 0.73 | MAPK1 (1.00) | PDE4APDE4BPDE4CPDE4DMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2018107200-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | PDE4A 1590/4885PDE4B 1743/4885PDE4C 2013/4885 |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | HPSE, HEXD, ENGASE | PDE4A 2726/4885PDE4B 2803/4885PDE4C 2724/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | PDE4A 2726/4885PDE4B 2803/4885PDE4C 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.